{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:31:53Z","timestamp":1789180313482,"version":"build-2803163510"},"reference-count":67,"publisher":"Bioscientifica","issue":"6","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":254,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Testosterone is the cornerstone therapy for men with hypogonadism, and also treats any associated anaemia by promoting erythropoiesis. However, excessive doses cause erythrocytosis (raised red cell mass), especially if other risk factors are present. Erythrocytosis is associated with arterial and venous thrombosis in population studies. Testosterone is now increasingly prescribed to older men with functional hypogonadism and obesity, hypertension or type 2 diabetes, who are anyway at higher risk of both erythrocytosis and thrombosis. Although short\u2013medium term testosterone treatment in these men was not associated with adverse cardiovascular outcomes, there were more cases of pulmonary embolism. Originally envisaged as purely oral hypoglycaemic drugs, sodium-glucose cotransporter 2 inhibitors (SGLT2i) are now increasingly prescribed in chronic kidney disease (CKD), ischaemic heart disease and left ventricular impairment, irrespective of glycaemia, and the likelihood of co-prescription with testosterone is thus increased considerably. Crucially, they also increase haematocrit by promoting haematopoiesis. This review focuses on the current best evidence for managing erythrocytosis, in the context of more prevalent obesity and prescriptions of testosterone and SGLT2i in this population. It highlights the need to balance the metabolic and therapeutic benefits against the potential risks. Management strategies include re-evaluating the original treatment indication, addressing modifiable risk factors, switching to transdermal testosterone and\/or reducing the testosterone dose. Venesection is not recommended, except for clonal erythrocytosis, due to its potential pro-thrombotic effects. However, combination therapy with testosterone and SGLT2s in men with anaemia of advanced CKD could augment, or even partly supersede, expensive treatment with conventional erythrocytosis-stimulating agents.<\/jats:p>","DOI":"10.1530\/ec-24-0695","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T13:17:25Z","timestamp":1749820645000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":7,"title":["Testosterone-induced erythrocytosis: addressing the challenge of metabolic syndrome and widely prescribed SGLT2-inhibitor drugs"],"prefix":"10.1530","volume":"14","author":[{"given":"Federica","family":"Tramontana","sequence":"first","affiliation":[{"name":"Department of Clinical & Experimental Medicine, Section of Pediatrics, University of Pisa 1 , ,","place":["Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azmi","family":"Mohammed","sequence":"additional","affiliation":[{"name":"Department of Endocrinology & Metabolism, John Hopkins Aramco Healthcare, KSA 2 , ,","place":["Dhahran, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6823-0473","authenticated-orcid":true,"given":"Yaasir H","family":"Mamoojee","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Newcastle Hospitals NHS Foundation Trust, The Royal Victoria Infirmary 3 , ,","place":["Newcastle-upon-Tyne, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4842-8095","authenticated-orcid":true,"given":"Richard","family":"Quinton","sequence":"additional","affiliation":[{"name":"Northern Region Gender Dysphoria Service, Cumbria Northumberland Tyne & Wear NHS Foundation Trust 4 , ,","place":["Newcastle-upon-Tyne, UK"]},{"name":"Department of Metabolism Digestion & Reproduction, Imperial College London 5 , ,","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"key":"2026070710592282300_bib1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/cen.14633","article-title":"Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism","volume":"96","author":"Jayasena","year":"2022","journal-title":"Clin Endocrinol"},{"key":"2026070710592282300_bib2","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1210\/jc.2009-1796","article-title":"Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European male ageing study","volume":"95","author":"Tajar","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070710592282300_bib3","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S2213-8587(24)00199-2","article-title":"Male hypogonadism: pathogenesis, diagnosis, and management","volume":"12","author":"De Silva","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026070710592282300_bib4","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3390\/clinpract13020041","article-title":"Treatment with testosterone therapy in type 2 diabetic hypogonadal adult males: a systematic review and meta-analysis","volume":"13","author":"Kumari","year":"2023","journal-title":"Clin Pract"},{"key":"2026070710592282300_bib5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1210\/js.2018-00186","article-title":"The anti-inflammatory effects of testosterone","volume":"3","author":"Bianchi","year":"2019","journal-title":"J Endocr Soc"},{"key":"2026070710592282300_bib6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fendo.2013.00071","article-title":"Adipokines mediate inflammation and insulin resistance","volume":"4","author":"Kwon","year":"2013","journal-title":"Front Endocrinol"},{"key":"2026070710592282300_bib7","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1210\/clinem\/dgae434","article-title":"Testosterone and erythrocyte lifespan","volume":"110","author":"McMartin","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070710592282300_bib8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S2213-8587(20)30367-3","article-title":"Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial","volume":"9","author":"Wittert","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026070710592282300_bib9","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1210\/clinem\/dgad485","article-title":"Long-term outcomes of testosterone treatment in men: a T4DM postrandomization observational follow-up study","volume":"109","author":"Handelsman","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070710592282300_bib10","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1016\/S2666-7568(22)00096-4","article-title":"Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis","volume":"3","author":"Hudson","year":"2022","journal-title":"Lancet Healthy Longevity"},{"key":"2026070710592282300_bib11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa2215025","article-title":"Cardiovascular safety of testosterone-replacement therapy","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026070710592282300_bib12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jamainternmed.2023.7862","article-title":"Effect of testosterone on progression from prediabetes to diabetes in men with hypogonadism: a substudy of the TRAVERSE randomized clinical trial","volume":"184","author":"Bhasin","year":"2024","journal-title":"JAMA Intern Med"},{"key":"2026070710592282300_bib13","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.cmet.2021.02.016","article-title":"A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors","volume":"33","author":"Sen","year":"2021","journal-title":"Cell Metab"},{"key":"2026070710592282300_bib14","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on water and sodium metabolism","volume":"13","author":"Tang","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026070710592282300_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-42989-z","article-title":"SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis","volume":"13","author":"Mavrakanas","year":"2023","journal-title":"Sci Rep"},{"key":"2026070710592282300_bib16","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1007\/s40618-024-02350-1","article-title":"Increased risk of erythrocytosis in men with type 2 diabetes treated with combined sodium-glucose cotransporter-2 inhibitor and testosterone replacement therapy","volume":"47","author":"Gosmanov","year":"2024","journal-title":"J Endocrinol Investig"},{"key":"2026070710592282300_bib17","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1681\/ASN.2019090944","article-title":"A randomized trial of empagliflozin to increase plasma sodium levels in patients with the syndrome of inappropriate antidiuresis","volume":"31","author":"Refardt","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2026070710592282300_bib18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ahj.2024.02.006","article-title":"Dapagliflozin and blood pressure in patients with chronic kidney disease and albuminuria","volume":"270","author":"Heerspink","year":"2024","journal-title":"Am Heart J"},{"key":"2026070710592282300_bib19","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2215\/CJN.0000000000000362","article-title":"Alleviation of anemia by SGLT2 inhibitors in patients with CKD: mechanisms and results of long-term placebo-controlled trials","volume":"19","author":"Packer","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026070710592282300_bib20","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation"},{"key":"2026070710592282300_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-080925","article-title":"SGLT-2 inhibitors and mortality among patients with heart failure with reduced ejection fraction: linked database study","volume":"387","author":"Svanstr\u00f6m","year":"2024","journal-title":"BMJ"},{"key":"2026070710592282300_bib22","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026070710592282300_bib23","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026070710592282300_bib24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.blre.2012.12.003","article-title":"Regulation of erythropoiesis by hypoxia-inducible factors","volume":"27","author":"Haase","year":"2013","journal-title":"Blood Rev"},{"key":"2026070710592282300_bib25","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1126\/science.1073440","article-title":"Structure of an HIF-1\u03b1-pVHL complex: hydroxyproline recognition in signaling","volume":"296","author":"Min","year":"2002","journal-title":"Science"},{"key":"2026070710592282300_bib26","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/bjh.15648","article-title":"A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline","volume":"184","author":"McMullin","year":"2019","journal-title":"Br J Haematol"},{"key":"2026070710592282300_bib27","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1210\/jc.2007-1692","article-title":"Effects of graded doses of testosterone on erythropoiesis in healthy young and older men","volume":"93","author":"Coviello","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070710592282300_bib28","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/gerona\/glt154","article-title":"Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin\/hemoglobin set point","volume":"69","author":"Bachman","year":"2014","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2026070710592282300_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2022.101653","article-title":"Haematological actions of androgens","volume":"36","author":"Warren","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"2026070710592282300_bib30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jsbmb.2008.12.007","article-title":"Testosterone action on erythropoiesis does not require its aromatization to estrogen: insights from the testosterone and estrogen treatment of two aromatase-deficient men","volume":"113","author":"Rochira","year":"2009","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2026070710592282300_bib31","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ijrobp.2004.11.008","article-title":"Effect of androgen suppression on hemoglobin in prostate cancer patients undergoing salvage radiotherapy plus 2-year buserelin acetate for rising PSA after surgery","volume":"62","author":"Chander","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026070710592282300_bib32","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/ejendo\/lvad099","article-title":"Leflutrozole in male obesity-associated hypogonadotropic hypogonadism: Ph 2b double-blind randomised controlled trial","volume":"189","author":"Jones","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"2026070710592282300_bib33","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1093\/ndt\/gfad171","article-title":"Sodium\u2013glucose co-transporter-2 inhibitor use and erythrocytosis: assessment of risk and need for referral to haematology","volume":"38","author":"Gangat","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2026070710592282300_bib34","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/jcmm.17115","article-title":"Effects of SGLT2 inhibitors on haematocrit and haemoglobin levels and the associated cardiorenal benefits in T2DM patients: a meta-analysis","volume":"26","author":"Tian","year":"2022","journal-title":"J Cell Mol Med"},{"key":"2026070710592282300_bib35","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000531084","article-title":"Mechanistic and clinical comparison of the erythropoietic effects of SGLT2 inhibitors and prolyl hydroxylase inhibitors in patients with chronic kidney disease and renal anemia","volume":"55","author":"Packer","year":"2024","journal-title":"Am J Nephrol"},{"key":"2026070710592282300_bib36","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1093\/eurheartj\/ehad235","article-title":"Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium\u2013glucose cotransporter 2 inhibitors","volume":"44","author":"Packer","year":"2023","journal-title":"Eur Heart J"},{"key":"2026070710592282300_bib37","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","article-title":"Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects","volume":"139","author":"Sano","year":"2019","journal-title":"Circulation"},{"key":"2026070710592282300_bib38","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1111\/jth.14574","article-title":"Arterial and venous thrombosis by high platelet count and high hematocrit: 108 521 individuals from the Copenhagen General Population Study","volume":"17","author":"Warny","year":"2019","journal-title":"J Thromb Haemostasis"},{"key":"2026070710592282300_bib39","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3324\/haematol.2009.008417","article-title":"Hematocrit and risk of venous thromboembolism in a general population. The Tromso study","volume":"95","author":"Braekkan","year":"2010","journal-title":"Haematologica"},{"key":"2026070710592282300_bib40","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1038\/s41375-021-01290-6","article-title":"JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views","volume":"35","author":"Gangat","year":"2021","journal-title":"Leukemia"},{"key":"2026070710592282300_bib41","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1161\/HYPERTENSIONAHA.112.193565","article-title":"Hemoglobin level is positively associated with blood pressure in a large cohort of healthy individuals","volume":"60","author":"Atsma","year":"2012","journal-title":"Hypertension"},{"key":"2026070710592282300_bib42","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/CRD.0000000000000443","article-title":"Gaisbock syndrome: a review of contemporary studies, pathogenesis, complications, and possible treatment","volume":"31","author":"Manal","year":"2023","journal-title":"Cardiol Rev"},{"key":"2026070710592282300_bib43","doi-asserted-by":"crossref","DOI":"10.1530\/EC-24-0283","article-title":"Testosterone therapy-induced erythrocytosis: can phlebotomy be justified?","volume":"13","author":"Bond","year":"2024","journal-title":"Endocr Connections"},{"key":"2026070710592282300_bib44","first-page":"E165","article-title":"Sodium-glucose co-transporter-2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases","volume":"98","author":"Gangat","year":"2023","journal-title":"Am J Hematol"},{"key":"2026070710592282300_bib45","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.3324\/haematol.2019.216267","article-title":"Thrombotic risk in congenital erythrocytosis due to up-regulated hypoxia sensing is not associated with elevated hematocrit","volume":"105","author":"Gordeuk","year":"2020","journal-title":"Haematologica"},{"key":"2026070710592282300_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2024.101930","article-title":"Testosterone-induced erythrocytosis in transgender males: challenges arising from an increasing prevalence of metabolic syndrome and wider therapeutic indications for prescribing SGLT2 inhibitor drugs","volume":"38","author":"Mohammed","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"2026070710592282300_bib47","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/ajh.26920","article-title":"JAK2 unmutated erythrocytosis: 2023 Update on diagnosis and management","volume":"98","author":"Gangat","year":"2023","journal-title":"Am J Hematol"},{"key":"2026070710592282300_bib48","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1530\/EJE-11-0221","article-title":"Onset of effects of testosterone treatment and time span until maximum effects are achieved","volume":"165","author":"Saad","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"2026070710592282300_bib49","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1001\/jamainternmed.2016.9540","article-title":"Association of testosterone levels with anemia in older men: a controlled clinical trial","volume":"177","author":"Roy","year":"2017","journal-title":"JAMA Intern Med"},{"key":"2026070710592282300_bib50","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaa119","article-title":"Longitudinal changes in hematologic parameters among transgender people receiving hormone therapy","volume":"4","author":"Antun","year":"2020","journal-title":"J Endocr Soc"},{"key":"2026070710592282300_bib51","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1210\/clinem\/dgab089","article-title":"Erythrocytosis in a Large cohort of trans men using testosterone: a long-term follow-up study on prevalence, determinants, and exposure years","volume":"106","author":"Madsen","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070710592282300_bib52","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.40030","article-title":"Efficacy of Testosterone replacement therapy in correcting anemia in men with hypogonadism: a randomized clinical trial","volume":"6","author":"Pencina","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026070710592282300_bib53","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/jch.14297","article-title":"Effects of the oral testosterone undecanoate KyzatrexTM on ambulatory blood pressure in hypogonadal men","volume":"23","author":"White","year":"2021","journal-title":"J Clin Hypertens"},{"key":"2026070710592282300_bib54","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/andr.12485","article-title":"Prospective evaluation of hematocrit in gender-affirming hormone treatment: results from European Network for the Investigation of Gender Incongruence","volume":"6","author":"Defreyne","year":"2018","journal-title":"Andrology"},{"key":"2026070710592282300_bib55","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1161\/01.CIR.100.16.1690","article-title":"Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease","volume":"100","author":"Webb","year":"1999","journal-title":"Circulation"},{"key":"2026070710592282300_bib56","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000272","article-title":"Testosterone and the cardiovascular system: a comprehensive review of the clinical literature","volume":"2","author":"Oskui","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"2026070710592282300_bib57","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa2308836","article-title":"Testosterone treatment and fractures in men with hypogonadism","volume":"390","author":"Snyder","year":"2024","journal-title":"N Engl J Med"},{"key":"2026070710592282300_bib58","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1530\/EC-19-0433","article-title":"Klinefelter syndrome and testosterone treatment: a national cohort study on thrombosis risk","volume":"9","author":"Chang","year":"2020","journal-title":"Endocr Connections"},{"key":"2026070710592282300_bib59","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/14740338.2024.2337741","article-title":"Cardiovascular safety of testosterone replacement therapy in men: an updated systematic review and meta-analysis","volume":"23","author":"Corona","year":"2024","journal-title":"Expet Opin Drug Saf"},{"key":"2026070710592282300_bib60","article-title":"Cardiovascular risk and mortality in men receiving testosterone replacement therapy for Klinefelter syndrome in Denmark: a retrospective cohort study","volume":"51","author":"Chang","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"2026070710592282300_bib61","doi-asserted-by":"crossref","first-page":"e3143","DOI":"10.1210\/clinem\/dgab149","article-title":"Effect of testosterone treatment on bone microarchitecture and bone mineral density in men: a 2-year RCT","volume":"106","author":"Ng Tang Fui","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070710592282300_bib62","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jamainternmed.2016.9539","article-title":"Effect of Testosterone treatment on volumetric bone density and strength in older men with low testosterone: a controlled clinical trial","volume":"177","author":"Snyder","year":"2017","journal-title":"JAMA Intern Med"},{"key":"2026070710592282300_bib63","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/j.jacc.2022.02.010","article-title":"Sex differences in cardiovascular consequences of hypertension, obesity, and diabetes","volume":"79","author":"Regensteiner","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026070710592282300_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2024.101907","article-title":"Metabolic and cardiovascular risks of hormone treatment for transgender individuals","volume":"38","author":"De Silva","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"2026070710592282300_bib65","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1161\/CIRCULATIONAHA.107.709204","article-title":"Cardiovascular risk factors and venous thromboembolism: a meta-analysis","volume":"117","author":"Ageno","year":"2008","journal-title":"Circulation"},{"key":"2026070710592282300_bib66","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41569-022-00787-6","article-title":"Epidemiology and prevention of venous thromboembolism","volume":"20","author":"Lutsey","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"2026070710592282300_bib67","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/cen.15146","article-title":"Androgen deficiency, associations and survival of men with stage 4 and 5 chronic kidney disease: a Cohort Study","volume":"102","author":"De Silva","year":"2024","journal-title":"Clin Endocrinol"}],"container-title":["Endocrine Connections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/14\/6\/EC-24-0695.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/14\/6\/EC-24-0695.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-24-0695\/9584\/ec-24-0695.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-24-0695\/9584\/ec-24-0695.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:27:28Z","timestamp":1783438048000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article\/14\/6\/e240695\/1405\/Testosterone-induced-erythrocytosis-addressing-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1530\/ec-24-0695","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,1]]},"article-number":"e240695"}}